- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02636907
Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe
Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bialystok, Poland, 15-099
- Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk
-
Bydgoszcz, Poland, 85-168
- Szpital Uniwersytecki nr 2 im.dr J. Biziela
-
Elblag, Poland, 82-300
- Wojewódzki Szpital Zespolony w Elblągu
-
Gdynia, Poland, 81-338
- Medica Pro Familia Spolka Akcyjna, Oddzial w Gdyni
-
Katowice, Poland, 40-954
- Medical Centre Pratia Katowice I
-
Krakow, Poland, 30-002
- Medical Centre Pratia Krakow
-
Krakow, Poland, 31-023
- Specialist Center ALL-MED, Krakow
-
Torun, Poland, 87-100
- Niepubliczny ZOZ, "Nasz Lekarz", Lekarzy Rodzinnych z
-
Warszawa, Poland, 01-868
- Medical Centre Pratia Warszawa
-
Wroclaw, Poland, 51-128
- Wojewodzki Szpital Specjalistyczny We Wroclawiu
-
-
-
-
California
-
Upland, California, United States, 91786
- Inland Rheumatology Clinical Trials, Inc.
-
-
Florida
-
Venice, Florida, United States, 34292
- Lovelace Scientific Resources, Incorporated
-
-
Maryland
-
Cumberland, Maryland, United States, 21502
- Klein and Associates, M.D., P.A.
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Clinical Pharmacology Study Group
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque Center for Rheumatology
-
-
Texas
-
Dallas, Texas, United States, 75231
- Metroplex Clinical Research Center
-
Houston, Texas, United States, 77065
- Rheumatology Clinic of Houston, P.A.
-
Lubbock, Texas, United States, 79424
- Arthritis & Osteoporosis Associates LLP
-
Nassau Bay, Texas, United States, 77058
- Heartland Research Associates, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Moderately to severely active Rheumatoid arthritis (RA) for at least 6 months, which is not adequately controlled by non-biologics DMARDs.
- No contraindications to anti-Tumor necrosis factor (TNF) agents.
- Either biologics naive or biologics-experienced but with no experience of self-administration medication using autoinjector or pen.
- Patients must be able and willing to self-inject BI 695501. Further inclusion criteria apply.
Exclusion criteria:
- Experience with self-administration of medication using an autoinjector or pen.
- American College of Rheumatology functional Class IV or wheelchair/ bed bound.
- Primary or secondary immunodeficiency.
- History of tuberculosis (TB). Further exclusion criteria apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BI 695501
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autoinjector Assessment Period: Percentage of Successful Self-injections as Reported in the Questionnaires Completed by Both the Trial Site Personnel and the Patient Analysing All Self-injections
Time Frame: Up to Day 50.
|
The percentage of successful self-injections as reported in the questionnaires completed by both the trial site personnel and the patient during the Autoinjector Assessment Period analyzing all self-injections occurring after the training self-injection up to the EoT Visit. Successful self-injections were based on the response to Question 2 (Q2) on the questionnaire, which queried whether the full content of the autoinjector was injected into the body. An injection was considered successful when both the patient and the qualified trial site personnel responded yes to the Q2 on their respective questionnaires. If they responded no to Q2, patients and trial site personnel were instructed to also answer Question 3, which asked what prevented the patient for injecting the full contents of the autoinjector. Planned injections after discontinuation from the trial were not included in the analysis. Percentage of injections calculated relative to the total number of first injections. |
Up to Day 50.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autoinjector Assessment Period: Percentage of Any Autoinjector Handling Events
Time Frame: Up to Day 50.
|
The percentage of any autoinjector handling event during the self-injection process included any one of the following events which prevented the patient from successfully self-injecting the full content of the autoinjector and which occurred after the training self-injection up to the EoT Visit: removing the cap of the autoinjector (3a); pressing the injection button of the autoinjector (3b); or holding the autoinjector down against the skin until the injection is completed (3c). Percentage of injections was calculated relative to the total number of injections (both unsuccessful and successful). |
Up to Day 50.
|
Autoinjector Assessment Period: The Percentage of Patients With Local Injection Site Reactions
Time Frame: Up to 17 weeks.
|
Qualified trial site personnel contacted the patient 48 hours after each self-injection during the autoinjector assessment period to collect all Adverse Events (AEs), including injection-site reactions. Data is reported as Treatment-Emergent AEs (TEAEs), defined as AEs that started or worsened on or after the first dose of trial medication during the treatment period and prior to the last date of trial medication during treatment period + 10 weeks (70 days) inclusive. The autoinjector assessment period started on the first autoinjector administration date (Day 1 visit) and ended on Day 50 visit date (included). If a TEAE occurred in the 10 weeks after the last autoinjector administration but prior to the first injection during the extension phase, it was to be accounted for in the autoinjector assessment period. Percentage of subjects calculated relative to the total number of subjects in the analysis set. |
Up to 17 weeks.
|
Autoinjector Assessment Period: The Percentage of Patients With Drug-related Adverse Events Per Investigator Assessment
Time Frame: Up to 17 weeks.
|
A treatment-related TEAE was defined as any TEAE assessed by the investigator as related to the trial medication.
Data is reported for the autoinjector assessment period.
TEAEs were defined as AEs that started or worsened on or after the first dose of trial medication during the treatment period and prior to the last date of trial medication during treatment period + 10 weeks (70 days) inclusive.
The autoinjector assessment period started on the first autoinjector administration date (Day 1 visit) and ended on Day 50 visit date (included).
If a TEAE occurred in the 10 weeks after the last autoinjector administration but prior to the first injection during the extension phase, it was to be accounted for in the autoinjector assessment period.
|
Up to 17 weeks.
|
Autoinjector Assessment Period and Extension Phase: The Percentage of Patients With Local Injection Site Reactions
Time Frame: up to Week 60
|
The percentage of patients with local injection site reactions in the Autoinjector assessment period and Extension Phase.
In Extension phase, patients were given diaries to record events between each site visit during extension phase.
Patients were instructed to accurately record the following on the diary cards: the dates & times of BI 695501 dosing; problems encountered with dosing; the occurrence of any AEs; the use of concomitant therapies; and the PFS storage conditions.
Patients were instructed to contact the site if they experienced any AEs between designated site visits.
In Extension phase Data is reported as Treatment-Emergent AEs (TEAEs), defined as AEs that started or worsened on or after the first PFS administration date (Day 57 visit) and after the 10 weeks of the last dose during the extension phase, it was to be accounted for in the Extension phase treatment period.
Percentage of subjects calculated relative to the total number of subjects in the analysis set
|
up to Week 60
|
Autoinjector Assessment Period and Extension Phase: The Percentage of Patients With Drug-related Adverse Events as Per Investigator Assessment
Time Frame: up to Week 60
|
The percentage of patients with drug-related adverse events as per investigator in the Autoinjector assessment period and Extension Phase.
In Extension phase, Treatment-Emergent AEs (TEAEs), defined as AEs that started or worsened on or after the first dose of trial medication and prior to the last date of trial medication during Extension phase treatment period + 10 weeks (70 days) inclusive.
The Extension phase treatment period started on the first PFS administration date (Day 57 visit) and ended on Day 351 visit date (included).
Thus If a TEAE occurred from the first PFS administration and after the 10 weeks of the last dose during the extension phase, it was to be accounted for in the Extension phase treatment period.
|
up to Week 60
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1297.11
- 2015-003030-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on BI 695501 Autoinjector
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedArthritis, RheumatoidUnited States, Spain, Korea, Republic of, Thailand, Malaysia, Poland, Russian Federation, Serbia, Bulgaria, Chile, Estonia, Germany, Hungary, Ukraine
-
Boehringer IngelheimCompletedCrohn DiseaseSerbia, United Kingdom, United States, Czechia, Germany, Greece, Poland, Russian Federation, Turkey, Israel, Belarus, Ukraine, Croatia, Bosnia and Herzegovina
-
Boehringer IngelheimCompletedPsoriasisUnited States, Germany, Russian Federation, Czechia, Poland, Ukraine, Estonia, Slovakia
-
AbbVieCompleted
-
Boehringer IngelheimCompletedPsoriasisUnited States, Poland, Hungary, Germany, Latvia, Russian Federation, Ukraine
-
Boehringer IngelheimCompletedArthritis, RheumatoidSpain, United States, Korea, Republic of, Malaysia, Poland, Thailand, Bulgaria, Chile, Estonia, Germany, Hungary, New Zealand, Russian Federation, Serbia, Ukraine
-
Boehringer IngelheimCompleted
-
AstraZenecaParexelCompletedHealthy Participants StudyGermany, United States, United Kingdom